Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions

The Clinical Curative Efficacy and Side Effect of Oligo-metastases Nasopharyngeal Carcinoma Patients Received Radical Radiation for Primary Tumors and Treatments for Metastatic Lesions

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03129412

Enrollment

Registered

2017-04-26

Start date

2017-04-14

Completion date

2025-04-23

Last updated

2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Cancer, Neoplasm Metastasis

Brief summary

Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.

Detailed description

The patients enrolled will received 4-6 cycles chemotherapy at first.Then, radical radiotherapy for nasopharyngeal tumors and local treatments for oligometastatic lesions will assigned to those patients. The efficacy and side-effect will be evaluated and analyzed.

Interventions

RADIATIONradical radiotherapy

radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Histologically conformed initial non-keratinizing squamous carcinoma in nasopharynx. 2. Clinical stages,T1-4N0-3M1，IVc(AJCC 2010). 3. The metastatic lesions ≤5 and metastatic organs ≤2 4. Karnofsky scores \>70 5. Normal hemodynamic indices before the recruitment (including white blood cell count\>4.0×109/L, neutrophil count\>1.5×109/L, platelet count \>100×109/L, hemoglobin≥90g/l, normal liver/kidney function). 6. Informed consent signed.

Exclusion criteria

1. Histologically conformed initial keratinizing carcinoma or others. 2. The metastatic lesions \>5 or metastatic organs \>2. 3. Any severe complications contraindicated chemotherapy or radiotherapy. 4. History of malignant tumors. 5. Pregnant or nursing women. 6. History of radiotherapy or chemotherpy in head and neck regions. 7. Patients refused the informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months	Events of death caused by any reasons

Secondary

Measure	Time frame	Description
Progress free survival	From date of diagnosis until the date of first documented progression, assessed up to 36 months	adverse event including death, recurrence and metastases.

Countries

China

Contacts

Primary ContactShuang Huang, Dr

huangshuang@zjcc.org.cn+8618258111085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026